Congressional task force seeks answers on the impact of the Inflation Reduction Act on drug development
Back
The House Budget Committee Health Care Task Force sent a letter to the nonpartisan Congressional Budget Office (CBO) requesting information on CBO’s analysis of policies impacting drug development in the United States, and asking for clarity on how CBO analyzed the impact of the Inflation Reduction Act (IRA) drug price controls on patient access to new drugs. CBO originally estimated that IRA price controls would lead to 13 fewer drugs being developed over the next 30 years, but independent analyses found there would be as many as 139 at risk of not being developed over the next 10 years. In October, CLS submitted a response to the Health Care Task Force’s request for information, specifically commenting on the need for CBO to reform how it scores health care legislation.